in the absence of a submission from the holder of the marketing authorisation:
tafasitamab (Minjuvi®) is not recommended for use within NHSScotland.
Indication under review: in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice289KB (PDF)
Medicine details
- Medicine name:
- tafasitamab (Minjuvi)
- SMC ID:
- SMC2943
- Indication:
Tafasitamab is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy.
- Pharmaceutical company
- Incyte Biosciences UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 June 2026